Notch signaling in neuroendocrine tumors

Frontiers in Oncology

Volumn 6, Issue APR, 2016, Pages

  Crabtree, Judy S ^a   Singleton, Ciera S ^a   Miele, Lucio ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoid; Neuroendocrine tumors; Notch; PNET; SCLC; Small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; EVEROLIMUS; NOTCH RECEPTOR; OCTREOTIDE; PEPTIDE HORMONE; TAREXTUMAB;

CAENORHABDITIS ELEGANS; CARCINOID; CELL FATE; CLINICAL TRIAL (TOPIC); DROSOPHILA; DRUG EFFICACY; DRUG TARGETING; ENTEROPANCREATIC NEUROENDOCRINE TUMOR; GENE; HORMONE RELEASE; HUMAN; IMMUNOHISTOCHEMISTRY; METASTASIS; MULTIPLE ENDOCRINE NEOPLASIA TYPE 2; NEUROENDOCRINE TUMOR; NONHUMAN; ONCOGENE; ONCOGENE MYC; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PULMONARY NEUROENDOCRINE TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; TREATMENT RESPONSE; TRIPLE NEGATIVE BREAST CANCER;

EID: 84973568957     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2016.00094     Document Type: Review

References (142)

1. Ayaz F, Osborne BA. Non-canonical notch signaling in cancer and immunity. Front Oncol (2014) 4:345. doi: 10.3389/fonc.2014.00345
2. Jin S, Mutvei AP, Chivukula IV, Andersson ER, Ramskold D, Sandberg R, et al. Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKKalpha/IKKbeta. Oncogene (2013) 32:4892-902. doi:10.1038/onc.2012.517
3. Kwon C, Cheng P, King IN, Andersen P, Shenje L, Nigam V, et al. Notch post-translationally regulates beta-catenin protein in stem and progenitor cells. Nat Cell Biol (2011) 13:1244-51. doi:10.1038/ncb2313
4. Perumalsamy LR, Nagala M, Banerjee P, Sarin A. A hierarchical cascade activated by non-canonical Notch signaling and the mTOR-Rictor complex regulates neglect-induced death in mammalian cells. Cell Death Differ (2009) 16:879-89. doi:10.1038/cdd.2009.20
5. Shin HM, Tilahun ME, Cho OH, Chandiran K, Kuksin CA, Keerthivasan S, et al. NOTCH1 can initiate NF-kappaB activation via cytosolic interactions with components of the T cell signalosome. Front Immunol (2014) 5:249. doi:10.3389/fimmu.2014.00249
6. Collu GM, Hidalgo-Sastre A, Brennan K. Wnt-Notch signalling crosstalk in development and disease. Cell Mol Life Sci (2014) 71:3553-67. doi:10.1007/s00018-014-1644-x
7. Bocchetta M, Miele L, Pass HI, Carbone M. Notch-1 induction, a novel activity of SV40 required for growth of SV40-transformed human mesothelial cells. Oncogene (2003) 22:81-9. doi:10.1038/sj.onc.1206097
8. Carter Y, Jaskula-Sztul R, Chen H, Mazeh H. Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch. Neuroendocrinology (2013) 97:57-66. doi:10.1159/000335136
9. Hassan WA, Yoshida R, Kudoh S, Hasegawa K, Niimori-Kita K, Ito T. Notch1 controls cell invasion and metastasis in small cell lung carcinoma cell lines. Lung Cancer (2014) 86:304-10. doi:10.1016/j.lungcan.2014.10.007
10. Krausch M, Kroepil F, Lehwald N, Lachenmayer A, Schott M, Anlauf M, et al. Notch 1 tumor expression is lacking in highly proliferative pancreatic neuroendocrine tumors. Endocrine (2013) 44:182-6. doi:10.1007/s12020-012-9850-5
11. Kunnimalaiyaan M, Chen H. Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist (2007) 12:535-42. doi:10.1634/theoncologist.12-5-535
12. Kunnimalaiyaan M, Yan S, Wong F, Zhang YW, Chen H. Hairy enhancer of split-1 (HES-1), a Notch1 effector, inhibits the growth of carcinoid tumor cells. Surgery (2005) 138:1137-42. doi:10.1016/j.surg.2005.05.027
13. Meder L, Konig K, Ozretic L, Schultheis AM, Ueckeroth F, Ade CP, et al. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas. Int J Cancer (2016) 138:927-38. doi:10.1002/ijc.29835
14. Saunders LR, Bankovich AJ, Anderson WC, Aujay MA, Bheddah S, Black K, et al. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med (2015) 7:302ra136. doi:10.1126/scitranslmed.aac9459
15. Andersson ER, Lendahl U. Therapeutic modulation of Notch signalling-are we there yet? Nat Rev Drug Discov (2014) 13:357-78. doi:10.1038/nrd4252
16. Chikara S, Reindl KM. Notch signaling: a hero or villain in the war against cancer? Transl Lung Cancer Res (2013) 2:449-51. doi:10.3978/j.issn.2218-6751.2013.10.15
17. D'Souza B, Miyamoto A, Weinmaster G. The many facets of Notch ligands. Oncogene (2008) 27:5148-67. doi:10.1038/onc.2008.229
18. Espinoza I, Miele L. Notch inhibitors for cancer treatment. Pharmacol Ther (2013) 139:95-110. doi:10.1016/j.pharmthera.2013.02.003
19. Heuss SF, Ndiaye-Lobry D, Six EM, Israel A, Logeat F. The intracellular region of Notch ligands Dll1 and Dll3 regulates their trafficking and signaling activity. Proc Natl Acad Sci U S A (2008) 105:11212-7. doi:10.1073/pnas.0800695105
20. Wang H, Zang C, Taing L, Arnett KL, Wong YJ, Pear WS, et al. NOTCH1-RBPJ complexes drive target gene expression through dynamic interactions with superenhancers. Proc Natl Acad Sci U S A (2014) 111:705-10. doi:10.1073/pnas.1315023111
21. Wu L, Aster JC, Blacklow SC, Lake R, Artavanis-Tsakonas S, Griffin JD. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet (2000) 26:484-9. doi:10.1038/82644
22. Jeffries S, Robbins DJ, Capobianco AJ. Characterization of a high-molecular-weight Notch complex in the nucleus of Notch(ic)-transformed RKE cells and in a human T-cell leukemia cell line. Mol Cell Biol (2002) 22:3927-41. doi:10.1128/MCB.22.11.3927-3941.2002
23. Kovall RA, Blacklow SC. Mechanistic insights into Notch receptor signaling from structural and biochemical studies. Curr Top Dev Biol (2010) 92:31-71. doi:10.1016/S0070-2153(10)92002-4
24. Vasquez-Del Carpio R, Kaplan FM, Weaver KL, VanWye JD, Alves-Guerra MC, Robbins DJ, et al. Assembly of a Notch transcriptional activation complex requires multimerization. Mol Cell Biol (2011) 31:1396-408. doi:10.1128/MCB.00360-10
25. Wallberg AE, Pedersen K, Lendahl U, Roeder RG. p300 and PCAF act cooperatively to mediate transcriptional activation from chromatin templates by notch intracellular domains in vitro. Mol Cell Biol (2002) 22:7812-9. doi:10.1128/MCB.22.22.7812-7819.2002
26. Kurooka H, Honjo T. Functional interaction between the mouse notch1 intracellular region and histone acetyltransferases PCAF and GCN5. J Biol Chem (2000) 275:17211-20. doi:10.1074/jbc.M000909200
27. Lai EC. Keeping a good pathway down: transcriptional repression of Notch pathway target genes by CSL proteins. EMBO Rep (2002) 3:840-5. doi:10.1093/embo-reports/kvf170
28. Kao HY, Ordentlich P, Koyano-Nakagawa N, Tang Z, Downes M, Kintner CR, et al. A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev (1998) 12:2269-77. doi:10.1101/gad.12.15.2269
29. Oswald F, Kostezka U, Astrahantseff K, Bourteele S, Dillinger K, Zechner U, et al. SHARP is a novel component of the Notch/RBP-Jkappa signalling pathway. EMBO J (2002) 21:5417-26. doi:10.1093/emboj/cdf549
30. Oswald F, Winkler M, Cao Y, Astrahantseff K, Bourteele S, Knochel W, et al. RBP-Jkappa/SHARP recruits CtIP/CtBP corepressors to silence Notch target genes. Mol Cell Biol (2005) 25:10379-90. doi:10.1128/MCB.25.23.10379-10390.2005
31. Hsieh JJ, Zhou S, Chen L, Young DB, Hayward SD. CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex. Proc Natl Acad Sci U S A (1999) 96:23-8. doi:10.1073/pnas.96.1.23
32. King IN, Kathiriya IS, Murakami M, Nakagawa M, Gardner KA, Srivastava D, et al. Hrt and Hes negatively regulate Notch signaling through interactions with RBP-Jkappa. Biochem Biophys Res Commun (2006) 345:446-52. doi:10.1016/j.bbrc.2006.04.097
33. Kim MY, Ann EJ, Mo JS, Dajas-Bailador F, Seo MS, Hong JA, et al. JIP1 binding to RBP-Jk mediates cross-talk between the Notch1 and JIP1-JNK signaling pathway. Cell Death Differ (2010) 17:1728-38. doi:10.1038/cdd.2010.50
34. Liefke R, Oswald F, Alvarado C, Ferres-Marco D, Mittler G, Rodriguez P, et al. Histone demethylase KDM5A is an integral part of the core Notch-RBP-J repressor complex. Genes Dev (2010) 24:590-601. doi:10.1101/gad.563210
35. Fryer CJ, White JB, Jones KA. Mastermind recruits CycC:CDK8 to phosphorylate the Notch ICD and coordinate activation with turnover. Mol Cell (2004) 16:509-20. doi:10.1016/j.molcel.2004.10.014
36. Oberg C, Li J, Pauley A, Wolf E, Gurney M, Lendahl U. The Notch intracellular domain is ubiquitinated and negatively regulated by the mammalian Sel-10 homolog. J Biol Chem (2001) 276:35847-53. doi:10.1074/jbc.M103992200
37. Wu G, Lyapina S, Das I, Li J, Gurney M, Pauley A, et al. SEL-10 is an inhibitor of notch signaling that targets notch for ubiquitin-mediated protein degradation. Mol Cell Biol (2001) 21:7403-15. doi:10.1128/MCB.21.21.7403-7415.2001
38. Ranganathan P, Vasquez-Del Carpio R, Kaplan FM, Wang H, Gupta A, VanWye JD, et al. Hierarchical phosphorylation within the ankyrin repeat domain defines a phosphoregulatory loop that regulates Notch transcriptional activity. J Biol Chem (2011) 286:28844-57. doi:10.1074/jbc.M111.243600
39. Foltz DR, Santiago MC, Berechid BE, Nye JS. Glycogen synthase kinase-3beta modulates notch signaling and stability. Curr Biol (2002) 12:1006-11. doi:10.1016/S0960-9822(02)00888-6
40. Moloney DJ, Panin VM, Johnston SH, Chen J, Shao L, Wilson R, et al. Fringe is a glycosyltransferase that modifies Notch. Nature (2000) 406:369-75. doi:10.1038/35019000
41. Moloney DJ, Shair LH, Lu FM, Xia J, Locke R, Matta KL, et al. Mammalian Notch1 is modified with two unusual forms of O-linked glycosylation found on epidermal growth factor-like modules. J Biol Chem (2000) 275:9604-11. doi:10.1074/jbc.275.13.9604
42. Okajima T, Xu A, Irvine KD. Modulation of notch-ligand binding by protein O-fucosyltransferase 1 and fringe. J Biol Chem (2003) 278:42340-5. doi:10.1074/jbc.M308687200
43. Bruckner K, Perez L, Clausen H, Cohen S. Glycosyltransferase activity of fringe modulates Notch-Delta interactions. Nature (2000) 406:411-5. doi:10.1038/35019075
44. Panin VM, Papayannopoulos V, Wilson R, Irvine KD. Fringe modulates Notch-ligand interactions. Nature (1997) 387:908-12. doi:10.1038/43191
45. Acar M, Jafar-Nejad H, Takeuchi H, Rajan A, Ibrani D, Rana NA, et al. Rumi is a CAP10 domain glycosyltransferase that modifies Notch and is required for Notch signaling. Cell (2008) 132:247-58. doi:10.1016/j.cell.2007.12.016
46. Lee TV, Sethi MK, Leonardi J, Rana NA, Buettner FF, Haltiwanger RS, et al. Negative regulation of notch signaling by xylose. PLoS Genet (2013) 9:e1003547. doi:10.1371/journal.pgen.1003547
47. Rana NA, Haltiwanger RS. Fringe benefits: functional and structural impacts of O-glycosylation on the extracellular domain of Notch receptors. Curr Opin Struct Biol (2011) 21:583-9. doi:10.1016/j.sbi.2011.08.008
48. Sethi MK, Buettner FF, Ashikov A, Krylov VB, Takeuchi H, Nifantiev NE, et al. Molecular cloning of a xylosyltransferase that transfers the second xylose to O-glucosylated epidermal growth factor repeats of notch. J Biol Chem (2012) 287:2739-48. doi:10.1074/jbc.M111.302406
49. Palermo R, Checquolo S, Giovenco A, Grazioli P, Kumar V, Campese AF, et al. Acetylation controls Notch3 stability and function in T-cell leukemia. Oncogene (2012) 31:3807-17. doi:10.1038/onc.2011.533
50. Popko-Scibor AE, Lindberg MJ, Hansson ML, Holmlund T, Wallberg AE. Ubiquitination of Notch1 is regulated by MAML1-mediated p300 acetylation of Notch1. Biochem Biophys Res Commun (2011) 416:300-6. doi:10.1016/j.bbrc.2011.11.030
51. Rustighi A, Tiberi L, Soldano A, Napoli M, Nuciforo P, Rosato A, et al. The prolyl-isomerase Pin1 is a Notch1 target that enhances Notch1 activation in cancer. Nat Cell Biol (2009) 11:133-42. doi:10.1038/ncb1822
52. Guarani V, Deflorian G, Franco CA, Kruger M, Phng LK, Bentley K, et al. Acetylation-dependent regulation of endothelial Notch signalling by the SIRT1 deacetylase. Nature (2011) 473:234-8. doi:10.1038/nature09917
53. Mulligan P, Yang F, Di Stefano L, Ji JY, Ouyang J, Nishikawa JL, et al. A SIRT1-LSD1 corepressor complex regulates Notch target gene expression and development. Mol Cell (2011) 42:689-99. doi:10.1016/j.molcel.2011.04.020
54. Ramakrishnan G, Davaakhuu G, Chung WC, Zhu H, Rana A, Filipovic A, et al. AKT and 14-3-3 regulate Notch4 nuclear localization. Sci Rep (2015) 5:8782. doi:10.1038/srep08782
55. Andersen P, Uosaki H, Shenje LT, Kwon C. Non-canonical Notch signaling: emerging role and mechanism. Trends Cell Biol (2012) 22:257-65. doi:10.1016/j.tcb.2012.02.003
56. Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am (2011) 40:1-18, vii. doi:10.1016/j.ecl.2010.12.005
57. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet (2003) 33:416-21. doi:10.1038/ng1099
58. Song LL, Peng Y, Yun J, Rizzo P, Chaturvedi V, Weijzen S, et al. Notch-1 associates with IKKalpha and regulates IKK activity in cervical cancer cells. Oncogene (2008) 27:5833-44. doi:10.1038/onc.2008.190
59. Hao L, Rizzo P, Osipo C, Pannuti A, Wyatt D, Cheung LW, et al. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells. Oncogene (2010) 29:201-13. doi:10.1038/onc.2009.323
60. Dongre A, Surampudi L, Lawlor RG, Fauq AH, Miele L, Golde TE, et al. Non-canonical Notch signaling drives activation and differentiation of peripheral CD4(+) T cells. Front Immunol (2014) 5:54. doi:10.3389/fimmu.2014.00054
61. Thome M. CARMA1, BCL-10 and MALT1 in lymphocyte development and activation. Nat Rev Immunol (2004) 4:348-59. doi:10.1038/nri1352
62. Minter LM, Osborne BA. Canonical and non-canonical Notch signaling in CD4(+) T cells. Curr Top Microbiol Immunol (2012) 360:99-114. doi:10.1007/82_2012_233
63. Meurette O, Stylianou S, Rock R, Collu GM, Gilmore AP, Brennan K. Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res (2009) 69:5015-22. doi:10.1158/0008-5472.CAN-08-3478
64. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, Diaz-Perez JA, Martinez Del Prado MP, Alonso Orduna V, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol (2010) 21:1794-803. doi:10.1093/annonc/mdq022
65. Mocellin S, Nitti D. Gastrointestinal carcinoid: epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol (2013) 24:3040-4. doi:10.1093/annonc/mdt377
66. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol (2008) 26:3063-72. doi:10.1200/JCO.2007.15.4377
67. Strosberg J. Neuroendocrine tumours of the small intestine. Best practice & research. Clin Gastroenterol (2012) 26:755-73. doi:10.1016/j.bpg.2012.12.002
68. Susini C, Buscail L. Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol (2006) 17:1733-42. doi:10.1093/annonc/mdl105
69. Cives M, Strosberg J. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors. Drugs (2015) 75:847-58. doi:10.1007/s40265-015-0397-7
70. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol (2009) 27:4656-63. doi:10.1200/JCO.2009.22.8510
71. Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med (2014) 371:224-33. doi:10.1056/NEJMoa1316158
72. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 364:514-23. doi:10.1056/NEJMoa1009290
73. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 364:501-13. doi:10.1056/NEJMoa1003825
74. Kunz PL. Carcinoid and neuroendocrine tumors: building on success. J Clin Oncol (2015) 33:1855-63. doi:10.1200/JCO.2014.60.2532
75. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 331:1199-203. doi:10.1126/science.1200609
76. Banck MS, Kanwar R, Kulkarni AA, Boora GK, Metge F, Kipp BR, et al. The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest (2013) 123:2502-8. doi:10.1172/JCI67963
77. Francis JM, Kiezun A, Ramos AH, Serra S, Pedamallu CS, Qian ZR, et al. Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. Nat Genet (2013) 45:1483-6. doi:10.1038/ng.2821
78. Swarts DR, Ramaekers FC, Speel EJ. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. Biochim Biophys Acta (2012) 1826:255-71. doi:10.1016/j.bbcan.2012.05.001
79. Travis WD. Advances in neuroendocrine lung tumors. Ann Oncol (2010) 7:vii65-71. doi:10.1093/annonc/mdq380
80. Detterbeck FC. Management of carcinoid tumors. Ann Thorac Surg (2010) 89:998-1005. doi:10.1016/j.athoracsur.2009.07.097
81. Besse B, Heist RS, Papadmitrakopoulou VA, Camidge DR, Beck JT, Schmid P, et al. A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer. Ann Oncol (2014) 25:505-11. doi:10.1093/annonc/mdt535
82. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet (2011) 378:2005-12. doi:10.1016/S0140-6736(11)61742-X
83. Han JY, Kim HY, Lim KY, Han JH, Lee YJ, Kwak MH, et al. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. Lung Cancer (2013) 79:137-42. doi:10.1016/j.lungcan.2012.09.019
84. Johnson BE, Fischer T, Fischer B, Dunlop D, Rischin D, Silberman S, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res (2003) 9:5880-7
85. Iwakawa R, Takenaka M, Kohno T, Shimada Y, Totoki Y, Shibata T, et al. Genome-wide identification of genes with amplification and/or fusion in small cell lung cancer. Genes Chromosomes Cancer (2013) 52:802-16. doi:10.1002/gcc.22076
86. Peifer M, Fernandez-Cuesta L, Sos ML, George J, Seidel D, Kasper LH, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 44:1104-10. doi:10.1038/ng.2396
87. Rudin CM, Durinck S, Stawiski EW, Poirier JT, Modrusan Z, Shames DS, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet (2012) 44:1111-6. doi:10.1038/ng.2405
88. Fernandez-Cuesta L, Peifer M, Lu X, Sun R, Ozretic L, Seidel D, et al. Frequent mutations in chromatin-remodelling genes in pulmonary carcinoids. Nat Commun (2014) 5:3518. doi:10.1038/ncomms4518
89. George J, Lim JS, Jang SJ, Cun Y, Ozretic L, Kong G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature (2015) 524:47-53. doi:10.1038/nature14664
90. Boora GK, Kanwar R, Kulkarni AA, Pleticha J, Ames M, Schroth G, et al. Exome-level comparison of primary well-differentiated neuroendocrine tumors and their cell lines. Cancer Genet (2015) 208:374-81. doi:10.1016/j.cancergen.2015.04.002
91. Espinoza I, Miele L. Deadly crosstalk: Notch signaling at the intersection of EMT and cancer stem cells. Cancer Lett (2013) 341:41-5. doi:10.1016/j.canlet.2013.08.027
92. Espinoza I, Pochampally R, Xing F, Watabe K, Miele L. Notch signaling: targeting cancer stem cells and epithelial-to-mesenchymal transition. Onco Targets Ther (2013) 6:1249-59. doi:10.2147/OTT.S36162
93. Zagouras P, Stifani S, Blaumueller CM, Carcangiu ML, Artavanis-Tsakonas S. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci U S A (1995) 92:6414-8. doi:10.1073/pnas.92.14.6414
94. Suzuki T, Aoki D, Susumu N, Udagawa Y, Nozawa S. Imbalanced expression of TAN-1 and human Notch4 in endometrial cancers. Int J Oncol (2000) 17:1131-9. doi:10.3892/ijo.17.6.1131
95. Subramaniam D, Ponnurangam S, Ramamoorthy P, Standing D, Battafarano RJ, Anant S, et al. Curcumin induces cell death in esophageal cancer cells through modulating Notch signaling. PLoS One (2012) 7:e30590. doi:10.1371/journal.pone.0030590
96. Yeh TS, Wu CW, Hsu KW, Liao WJ, Yang MC, Li AF, et al. The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res (2009) 69:5039-48. doi:10.1158/0008-5472.CAN-08-4021
97. Purow BW, Haque RM, Noel MW, Su Q, Burdick MJ, Lee J, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 65:2353-63. doi:10.1158/0008-5472.CAN-04-1890
98. Leethanakul C, Patel V, Gillespie J, Pallente M, Ensley JF, Koontongkaew S, et al. Distinct pattern of expression of differentiation and growth-related genes in squamous cell carcinomas of the head and neck revealed by the use of laser capture microdissection and cDNA arrays. Oncogene (2000) 19:3220-4. doi:10.1038/sj.onc.1203703
99. Wang M, Xue L, Cao Q, Lin Y, Ding Y, Yang P, et al. Expression of Notch1, Jagged1 and beta-catenin and their clinicopathological significance in hepatocellular carcinoma. Neoplasma (2009) 56:533-41. doi:10.4149/neo_2009_06_533
100. Dang TP, Gazdar AF, Virmani AK, Sepetavec T, Hande KR, Minna JD, et al. Chromosome 19 translocation, overexpression of Notch3, and human lung cancer. J Natl Cancer Inst (2000) 92:1355-7. doi:10.1093/jnci/92.16.1355
101. Fan X, Mikolaenko I, Elhassan I, Ni X, Wang Y, Ball D, et al. Notch1 and notch2 have opposite effects on embryonal brain tumor growth. Cancer Res (2004) 64:7787-93. doi:10.1158/0008-5472.CAN-04-1446
102. Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, et al. Activation of Notch1 signaling is required for beta-catenin-mediated human primary melanoma progression. J Clin Invest (2005) 115:3166-76. doi:10.1172/JCI25001
103. McAuliffe SM, Morgan SL, Wyant GA, Tran LT, Muto KW, Chen YS, et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A (2012) 109:E2939-48. doi:10.1073/pnas.1206400109
104. Miyamoto Y, Maitra A, Ghosh B, Zechner U, Argani P, Iacobuzio-Donahue CA, et al. Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 3:565-76. doi:10.1016/S1535-6108(03)00140-5
105. Santagata S, Demichelis F, Riva A, Varambally S, Hofer MD, Kutok JL, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res (2004) 64:6854-7. doi:10.1158/0008-5472.CAN-04-2500
106. Rae FK, Stephenson SA, Nicol DL, Clements JA. Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display. Int J Cancer (2000) 88:726-32. doi:10.1002/1097-0215(20001201)88:5<726::AID-IJC7>3.0.CO;2-H
107. Raimondi L, Ciarapica R, De Salvo M, Verginelli F, Gueguen M, Martini C, et al. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo. Cell Death Differ (2012) 19:871-81. doi:10.1038/cdd.2011.171
108. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell (1991) 66:649-61. doi:10.1016/0092-8674(91)90111-B
109. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 306:269-71. doi:10.1126/science.1102160
110. Jundt F, Anagnostopoulos I, Forster R, Mathas S, Stein H, Dorken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood (2002) 99:3398-403. doi:10.1182/blood.V99.9.3398
111. Tohda S, Nara N. Expression of Notch1 and Jagged1 proteins in acute myeloid leukemia cells. Leuk Lymphoma (2001) 42:467-72. doi:10.3109/10428190109064603
112. Hajdu M, Kopper L, Sebestyen A. Notch-regulation upon Dll4-stimulation of TGFb-induced apoptosis and gene expression in human B-cell non-Hodgkin lymphomas. Scand J Immunol (2010) 71:29-37. doi:10.1111/j.1365-3083.2009.02346.x
113. Jundt F, Probsting KS, Anagnostopoulos I, Muehlinghaus G, Chatterjee M, Mathas S, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood (2004) 103:3511-5. doi:10.1182/blood-2003-07-2254
114. Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. Nat Rev Neurosci (2006) 7:93-102. doi:10.1038/nrn1847
115. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science (1999) 284:770-6. doi:10.1126/science.284.5415.770
116. Kunnimalaiyaan M, Traeger K, Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol (2005) 289:G636-42. doi:10.1152/ajpgi.00146.2005
117. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, Chen H. Overexpression of the NOTCH1 intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem (2006) 281:39819-30. doi:10.1074/jbc.M603578200
118. Nakakura EK, Sriuranpong VR, Kunnimalaiyaan M, Hsiao EC, Schuebel KE, Borges MW, et al. Regulation of neuroendocrine differentiation in gastrointestinal carcinoid tumor cells by notch signaling. J Clin Endocrinol Metab (2005) 90:4350-6. doi:10.1210/jc.2005-0540
119. Shida T, Furuya M, Nikaido T, Hasegawa M, Koda K, Oda K, et al. Sonic Hedgehog-Gli1 signaling pathway might become an effective therapeutic target in gastrointestinal neuroendocrine carcinomas. Cancer Biol Ther (2006) 5:1530-8. doi:10.4161/cbt.5.11.3458
120. Wang H, Chen Y, Fernandez-Del Castillo C, Yilmaz O, Deshpande V. Heterogeneity in signaling pathways of gastroenteropancreatic neuroendocrine tumors: a critical look at notch signaling pathway. Mod Pathol (2013) 26:139-47. doi:10.1038/modpathol.2012.143
121. Eliasz S, Liang S, Chen Y, De Marco MA, Machek O, Skucha S, et al. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene (2010) 29:2488-98. doi:10.1038/onc.2010.7
122. Sriuranpong V, Borges MW, Ravi RK, Arnold DR, Nelkin BD, Baylin SB, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. Cancer Res (2001) 61:3200-5
123. Jaskula-Sztul R, Eide J, Tesfazghi S, Dammalapati A, Harrison AD, Yu XM, et al. Tumor-suppressor role of Notch3 in medullary thyroid carcinoma revealed by genetic and pharmacological induction. Mol Cancer Ther (2015) 14:499-512. doi:10.1158/1535-7163.MCT-14-0073
124. Zhou M, Jin WY, Fan ZW, Han RC. Analysis of the expression of the Notch3 receptor protein in adult lung cancer. Oncol Lett (2013) 5:499-504. doi:10.3892/ol.2012.1033
125. Ito T, Udaka N, Yazawa T, Okudela K, Hayashi H, Sudo T, et al. Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium. Development (2000) 127:3913-21
126. Morimoto M, Nishinakamura R, Saga Y, Kopan R. Different assemblies of Notch receptors coordinate the distribution of the major bronchial Clara, ciliated and neuroendocrine cells. Development (2012) 139:4365-73. doi:10.1242/dev.083840
127. Massi D, Panelos J. Notch signaling and the developing skin epidermis. Adv Exp Med Biol (2012) 727:131-41. doi:10.1007/978-1-4614-0899-4_10
128. Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 333:1154-7. doi:10.1126/science.1206923
129. Liu Z, Turkoz A, Jackson EN, Corbo JC, Engelbach JA, Garbow JR, et al. Notch1 loss of heterozygosity causes vascular tumors and lethal hemorrhage in mice. J Clin Invest (2011) 121:800-8. doi:10.1172/JCI43114
130. Li X, Zhang X, Leathers R, Makino A, Huang C, Parsa P, et al. Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat Med (2009) 15:1289-97. doi:10.1038/nm.2021
131. Wang J, Scully K, Zhu X, Cai L, Zhang J, Prefontaine GG, et al. Opposing LSD1 complexes function in developmental gene activation and repression programmes. Nature (2007) 446:882-7. doi:10.1038/nature05671
132. Borggrefe T, Liefke R. Fine-tuning of the intracellular canonical Notch signaling pathway. Cell Cycle (2012) 11:264-76. doi:10.4161/cc.11.2.18995
133. Miele L. Transcription factor RBPJ/CSL: a genome-wide look at transcriptional regulation. Proc Natl Acad Sci U S A (2011) 108:14715-6. doi:10.1073/pnas.1110570108
134. Wang H, Zou J, Zhao B, Johannsen E, Ashworth T, Wong H, et al. Genome-wide analysis reveals conserved and divergent features of Notch1/RBPJ binding in human and murine T-lymphoblastic leukemia cells. Proc Natl Acad Sci U S A (2011) 108:14908-13. doi:10.1073/pnas.1109023108
135. Zhao B, Zou J, Wang H, Johannsen E, Peng CW, Quackenbush J, et al. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci U S A (2011) 108:14902-7. doi:10.1073/pnas.1108892108
136. Graziani I, Eliasz S, De Marco MA, Chen Y, Pass HI, De May RM, et al. Opposite effects of Notch-1 and Notch-2 on mesothelioma cell survival under hypoxia are exerted through the Akt pathway. Cancer Res (2008) 68:9678-85. doi:10.1158/0008-5472.CAN-08-0969
137. Parr C, Watkins G, Jiang WG. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med (2004) 14:779-86. doi:10.3892/ijmm.14.5.779
138. Sun Y, Klauzinska M, Lake RJ, Lee JM, Santopietro S, Raafat A, et al. Trp53 regulates Notch 4 signaling through Mdm2. J Cell Sci (2011) 124:1067-76. doi:10.1242/jcs.068965
139. Osipo C, Golde TE, Osborne BA, Miele LA. Off the beaten pathway: the complex cross talk between Notch and NF-kappaB. Lab Invest (2008) 88:11-7. doi:10.1038/labinvest.3700700
140. Raafat A, Lawson S, Bargo S, Klauzinska M, Strizzi L, Goldhar AS, et al. Rbpj conditional knockout reveals distinct functions of Notch4/Int3 in mammary gland development and tumorigenesis. Oncogene (2009) 28:219-30. doi:10.1038/onc.2008.379
141. Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med (2011) 17:1646-51. doi:10.1038/nm.2580
142. Yen WC, Fischer MM, Axelrod F, Bond C, Cain J, Cancilla B, et al. Targeting Notch signaling with a Notch2/Notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res (2015) 21:2084-95. doi:10.1158/1078-0432.CCR-14-2808